IL17A and atherosclerosis: KEGG pathway enrichment analysis revealed that GJZLP treatment for tuberculosis could target multiple signaling pathways, primarily including Lipid metabolism, Atherosclerosis, TNF, IL-17, Toll-like receptor and C-type lectin receptor signaling pathway.